Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument
Bio-Techne (NASDAQ: TECH) has expanded its partnership with Leica Biosystems to enhance spatial multiomics research capabilities. The collaboration focuses on automating Bio-Techne's new RNAscope™ Multiomic LS Assay on Leica's BOND RX research staining instrument.
The assay enables simultaneous detection of up to six RNA and/or protein biomarkers on a single slide while preserving sample integrity. Additionally, they introduced a protease-free workflow for RNAscope™ 2.5 single-plex assays. The RNAscope™ technology has been widely adopted globally, contributing to over 12,000 peer-reviewed publications.
This expansion builds upon their partnership established in 2015, focusing on automated in-situ hybridization workflows for spatial biology research.
Bio-Techne (NASDAQ: TECH) ha ampliato la sua partnership con Leica Biosystems per migliorare le capacità di ricerca nella multiomica spaziale. La collaborazione si concentra sull'automazione del nuovo RNAscope™ Multiomic LS Assay di Bio-Techne sull'apparecchiatura di colorazione per ricerca BOND RX di Leica.
Il test consente la rilevazione simultanea di fino a sei biomarcatori RNA e/o proteici su un'unica slide, preservando l'integrità del campione. Inoltre, è stato introdotto un flusso di lavoro privo di proteasi per gli assay RNAscope™ 2.5 a singolo plex. La tecnologia RNAscope™ è stata ampiamente adottata a livello globale, contribuendo a oltre 12.000 pubblicazioni peer-reviewed.
Questa espansione si basa sulla loro partnership stabilita nel 2015, focalizzandosi su flussi di lavoro di ibridezazione in situ automatizzati per la ricerca in biologia spaziale.
Bio-Techne (NASDAQ: TECH) ha ampliado su asociación con Leica Biosystems para mejorar las capacidades de investigación en multiómicas espaciales. La colaboración se centra en la automatización del nuevo RNAscope™ Multiomic LS Assay de Bio-Techne en el instrumento de tinción de investigación BOND RX de Leica.
El ensayo permite la detección simultánea de hasta seis biomarcadores de ARN y/o proteínas en un solo portaobjetos, preservando la integridad de la muestra. Además, se introdujo un flujo de trabajo libre de proteasas para los ensayos de un solo plex RNAscope™ 2.5. La tecnología RNAscope™ ha sido adoptada ampliamente a nivel mundial, contribuyendo a más de 12,000 publicaciones revisadas por pares.
Esta expansión se basa en la asociación establecida en 2015, enfocándose en flujos de trabajo de hibridación in situ automatizados para la investigación en biología espacial.
Bio-Techne (NASDAQ: TECH)는 Leica Biosystems와의 파트너십을 확장하여 공간 다중 오믹스 연구 능력을 향상시켰습니다. 이 협력은 Bio-Techne의 새로운 RNAscope™ Multiomic LS Assay를 Leica의 BOND RX 연구 염색 기기에서 자동화하는 데 중점을 두고 있습니다.
이 분석법은 샘플의 무결성을 유지하면서 단일 슬라이드에서 최대 여섯 개의 RNA 및/또는 단백질 바이오마커를 동시에 감지할 수 있게 해줍니다. 또한, RNAscope™ 2.5 단일 플렉스 분석을 위한 단백분해효소가 없는 작업 흐름이 도입되었습니다. RNAscope™ 기술은 전 세계적으로 널리 채택되어 12,000개 이상의 동료 검토 출판물에 기여하고 있습니다.
이번 확장은 2015년에 설정된 파트너십을 기반으로 하여 공간 생물학 연구를 위한 자동화된 인시투 하이브리다이제이션 작업 흐름에 초점을 맞추고 있습니다.
Bio-Techne (NASDAQ: TECH) a élargi son partenariat avec Leica Biosystems pour améliorer les capacités de recherche en multiomique spatiale. La collaboration se concentre sur l'automatisation du nouveau RNAscope™ Multiomic LS Assay de Bio-Techne sur l'instrument de coloration de recherche BOND RX de Leica.
Ce test permet la détection simultanée de jusqu'à six biomarqueurs d'ARN et/ou de protéines sur une seule lame tout en préservant l'intégrité de l'échantillon. De plus, un flux de travail sans protéase a été introduit pour les essais à un seul plex RNAscope™ 2.5. La technologie RNAscope™ a été largement adoptée à l'échelle mondiale, contribuant à plus de 12 000 publications évaluées par des pairs.
Cette expansion s'appuie sur leur partenariat établi en 2015, axé sur les flux de travail d'hybridation in situ automatisés pour la recherche en biologie spatiale.
Bio-Techne (NASDAQ: TECH) hat seine Partnerschaft mit Leica Biosystems erweitert, um die Forschungsfähigkeiten im Bereich der räumlichen Multiomics zu verbessern. Die Zusammenarbeit konzentriert sich auf die Automatisierung des neuen RNAscope™ Multiomic LS Assay von Bio-Techne auf dem Forschungsfärbeinstrument BOND RX von Leica.
Der Assay ermöglicht die gleichzeitige Erkennung von bis zu sechs RNA- und/oder Protein-Biomarkern auf einem einzigen Objektträger, während die Integrität der Probe gewahrt bleibt. Darüber hinaus wurde ein proteasefreier Arbeitsablauf für die RNAscope™ 2.5 Einzelplex-Assays eingeführt. Die RNAscope™-Technologie wurde weltweit breit angenommen und hat zu über 12.000 peer-reviewed Publikationen beigetragen.
Diese Erweiterung baut auf der 2015 gegründeten Partnerschaft auf, die sich auf automatisierte In-situ-Hybridisierungs-Workflows für die Forschung in der räumlichen Biologie konzentriert.
- Expansion of technological capabilities with new RNAscope Multiomic LS Assay
- Strong market adoption evidenced by 12,000+ peer-reviewed publications
- Enhanced product offering through protease-free workflow introduction
- None.
Insights
Bio-Techne's expanded partnership with Leica Biosystems enhances their spatial biology capabilities through automation of the RNAscope™ Multiomic LS Assay on Leica's BOND RX platform. This advancement solves a significant technical challenge by enabling simultaneous visualization of up to six RNA/protein biomarkers on a single tissue slide while preserving sample integrity.
The newly introduced protease-free workflow represents a technical improvement that addresses a key pain point in spatial biology research - maintaining both RNA and protein integrity during the detection process. This preservation of biomolecule quality and tissue morphology is crucial for generating reliable multiomics data.
With over 12,000 peer-reviewed publications citing RNAscope technology, Bio-Techne has established significant scientific validation. The automation element streamlines complex spatial biology workflows, potentially reducing hands-on time and improving reproducibility - critical factors for adoption in pharmaceutical research settings.
While technically significant, this represents an incremental advancement within Bio-Techne's established spatial biology franchise rather than a revolutionary new product line. The partnership builds on seven years of collaboration with Leica, suggesting continued execution of Bio-Techne's spatial biology strategy within their Diagnostics & Spatial Biology segment.
This partnership expansion reinforces Bio-Techne's position in the growing spatial biology market, but its financial impact appears incremental rather than transformative. The enhanced automation capabilities could improve adoption rates of Bio-Techne's RNAscope technology among research institutions and pharmaceutical companies, potentially driving reagent consumption.
The development aligns with Bio-Techne's strategy to expand its Diagnostics & Spatial Biology segment through technology improvements and strategic partnerships. The protease-free workflow might create competitive differentiation and strengthen Bio-Techne's value proposition in the research market.
However, the announcement lacks quantifiable financial metrics or market opportunity sizing. As a research-use-only technology advancement, revenue impact will likely build gradually through increased reagent and assay kit sales rather than through immediate large-scale system placements. The 2015 partnership foundation suggests this is evolution of an existing revenue stream rather than creation of an entirely new one.
Bio-Techne's continued innovation in spatial biology tools demonstrates commitment to this growth segment, but with no financial terms disclosed and the technology to research applications (not diagnostic procedures), investors should view this as a positive but incremental development within the company's existing spatial biology commercialization roadmap.
The RNAscope™ Multiomic LS Assay enables simultaneous fluorescent detection of up to six RNA and/or protein biomarkers on the same slide, preserving RNA and protein integrity while maintaining tissue morphology. Additionally, ACD introduced a protease-free workflow for RNAscope™ 2.5 single-plex assays on the Leica BOND RX staining instrument, further advancing multiomic visualization from discovery research to translational applications.
"The automation of Bio-Techne's innovative RNAscope™ protease-free assays on the Leica BOND RX platform marks a significant milestone in spatial multiomics research," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "High-precision visualization of RNA and protein biomarkers on the same slide empowers researchers with a streamlined, fully automated solution that preserves sample integrity and accelerates scientific discoveries in translational and clinical research."
The RNAscope™ in situ spatial assays have been widely adopted by top academic institutions, pharmaceutical companies, and service providers worldwide, contributing to over 12,000 peer-reviewed publications. This expansion builds on the strong partnership between Bio-Techne and Leica Biosystems, established in 2015, to deliver automated in-situ hybridization (ISH) workflows that streamline spatial biology research.
"At Leica Biosystems, we are committed to empowering researchers with innovative automation solutions that accelerate spatial biology discovery," said Karan Arora, Senior Vice President of Advanced Assays at Leica Biosystems. "The integration of ACD's RNAscope™ Multiomic LS Assay on the BOND RX reinforces our mission to provide cutting-edge tools that enhance precision and scalability in life science research."
To learn more about Bio-Techne's in-situ spatial assays automated on the BOND RX research staining instrument, visit: https://www.leicabiosystems.com/us/life-sciences-and-research-solutions/partners/acd/
For Research Use Only. Not For Use In Diagnostic Procedures.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Leica Biosystems is headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/leica-biosystems-and-bio-techne-expand-partnership-to-enable-protease-free-workflows-for-automated-spatial-multiomics-on-the-bond-rx-research-staining-instrument-302417850.html
SOURCE Bio-Techne Corporation
FAQ
What is the new RNAscope Multiomic LS Assay capability announced by Bio-Techne (TECH)?
How many peer-reviewed publications have featured Bio-Techne's (TECH) RNAscope technology?
When did Bio-Techne (TECH) and Leica Biosystems initially establish their partnership?
What new workflow improvement has Bio-Techne (TECH) introduced for RNAscope 2.5?
